The Acute Effects of Capsiate During Exercise
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Capsiate is a non-pungent analogue of capsaicin, the component of hot peppers that makes them hot or spicy. Unlike capsaicin, capsiate is not spicy or hot. Ingestion of capsiate has been shown to increase resting oxygen consumption, body temperature, and the burning of fat. As such, capsiate appears to act in a manner similar to that of many other substances that energize us, increase our alertness and cause a rushing feeling by affecting a system in our body that is responsible for the release of adrenaline. The major difference, however, is that capsiate is broken down in the stomach into two components: vanilla and a fatty acid, and is not absorbed as capsiate into the blood stream at all. This implies that the way capsiate works is likely by acting on the cells in the gut (before it is broken down)rather than affecting all other cells in the body as it would do if it ended up in the blood. Therefore, the gut cells are thought to be the ones responsible for triggering the full-body adrenaline response. In any case, the use of capsiate has been shown to be effective in preventing weight gain and as such it may represent a possible therapy for treating obesity. Many obesity-related programs not involving medication advocate the use of diet and/or exercise. However, one of the biggest problems with weight loss from dieting alone is a general decrease in our body's ability to burn the food we eat as energy. This very problem is the reason for why people turn to adrenaline-releasing drugs like caffeine and ephedra. Unfortunately though, if too much is consumed, there is a high risk of bad side-effects. However, low dose caffeine/ephedra compounds (that are within specified FDA limits) have recently been reported to be effective. Moreover, these compounds are used with great frequency by people attempting to lose weight.
Given that capsiate increases body temperature, promotes the burning of body fat and has an exceptionally great side-effect profile, it looks to be a very effective supplement for use in treatment of obesity and overweight. As such, it would be important to test this supplement along with exercise. This is because consuming capsiate with exercise may enhance its effectiveness in increasing the burning of body fat. The primary purpose of this study is to examine the response of young healthy males to a 90 minute bout of moderate intensity cycling after having consumed 0 mg, 3 mg, or 10 mg of capsiate.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy |
Dietary Supplement: Acute consumption of Capsiate Natura Dietary Supplement: Acute ingestion of identical placebo capsules |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Basic Science |
| Official Title: | Effect of Differing Doses of A Sweet Pepper Extract - Capsiate (A Capsaicin Analogue) - On Energy Expenditure and Blood Parameters in Humans During Exercise |
- Respiratory Exchange Ratio (RER) for substrate use [ Time Frame: breath by breath analysis of oxygen uptake and carbon dioxide release (recorded as the average oxygen uptake and carbon dioxide relsease every 30 seconds) ] [ Designated as safety issue: No ]
- Heart Rate [ Time Frame: measured 8 times over 180 minutes ] [ Designated as safety issue: No ]
- Blood Pressure monitoring [ Time Frame: measured 8 times over 180 minutes ] [ Designated as safety issue: No ]
- Blood biomarkers (blood glucose, glycerol, lactate, Free fatty acids [FFA]) [ Time Frame: measured 6 times over 180 minutes ] [ Designated as safety issue: No ]
- Plasma Catecholamines (Epinephrine, norepinephrine) [ Time Frame: measured 6 times over 180 minutes ] [ Designated as safety issue: No ]
| Enrollment: | 12 |
| Study Start Date: | April 2008 |
| Study Completion Date: | September 2008 |
| Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
acute oral ingestion of 3 mg capsiate
|
Dietary Supplement: Acute consumption of Capsiate Natura
10 capsules = 3 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. 3 active capsules containing 1 mg capsiate each and 7 placebo capsules.
Other Name: Brand: Capsiate Natura, Capsinoid
|
|
Experimental: 2
acute oral ingestion of 10 mg capsiate
|
Dietary Supplement: Acute consumption of Capsiate Natura
10 capsules = 10 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
Other Name: Brand: Capsiate Natura
|
|
Placebo Comparator: 3
acute oral ingestion of 0 mg capsiate ( same number of capsules as two other trials and identical looking placebo capsules)
|
Dietary Supplement: Acute ingestion of identical placebo capsules
10 mg placebo = 0 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 30 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy men
- Recreationally active
- Non-smokers
- Age 18-30 years
- Favourable (low risk) answers on Standard Health Questionnaire (part of approved consent form)
- Peak VO2 of > 40 ml/kg/min
- Recruited from the local McMaster University campus or surrounding community.
Exclusion Criteria:
- Women
- Smokers
- Contraindicated health conditions which would render someone "clinically" unhealthy i.e. diabetes, liver, kidney abnormalities, etc.
- Possible allergies to the study products (Capsiate or Placebo)
- The use of foods, other natural health products or pharmaceuticals that may interact with the study products
- The use of natural health products that alter the outcome measures of the trial
Contacts and Locations| Canada, Ontario | |
| Exercise Metabolism Research Laboratory, McMaster Univeristy | |
| Hamilton, Ontario, Canada, L8S 4K1 | |
| Principal Investigator: | Stuart M Phillips, Ph.D. | Department of Kinesiology, McMaster University |
| Study Director: | Andrea R Josse, M.Sc. | Department of Kinesiology, McMaster University |
| Study Director: | Nicholas A Burd, M.Sc. | Department of Kinesiology, McMaster University |
| Study Chair: | Yoshiyuki Fujishima, D.Phil. | Ajinomoto USA, INC. |
More Information
Publications:
| Responsible Party: | Stuart M Phillips, Associate Professor, Department of Kinesiology, McMaster University |
| ClinicalTrials.gov Identifier: | NCT00692601 History of Changes |
| Other Study ID Numbers: | REB 07-410, NHPD#:130269 |
| Study First Received: | June 4, 2008 |
| Last Updated: | September 15, 2008 |
| Health Authority: | Canada: Health Canada |
Keywords provided by McMaster University:
|
Acute Exercise protocol Crossover design Oxygen consumption (VO2) Respiratory Exchange Ratio (RER) |
Adrenergic System Agonism Capsiate Natura Young Male |
ClinicalTrials.gov processed this record on May 23, 2013